386 related articles for article (PubMed ID: 23045248)
1. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
[TBL] [Abstract][Full Text] [Related]
2. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
[TBL] [Abstract][Full Text] [Related]
7. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Song N; Pogue-Geile KL; Gavin PG; Yothers G; Kim SR; Johnson NL; Lipchik C; Allegra CJ; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S
JAMA Oncol; 2016 Sep; 2(9):1162-9. PubMed ID: 27270348
[TBL] [Abstract][Full Text] [Related]
9. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
10. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
12. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
Sinicrope FA; Mahoney MR; Yoon HH; Smyrk TC; Thibodeau SN; Goldberg RM; Nelson GD; Sargent DJ; Alberts SR;
Clin Cancer Res; 2015 Dec; 21(23):5294-304. PubMed ID: 26187617
[TBL] [Abstract][Full Text] [Related]
14. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
15. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
16. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.
Taieb J; Zaanan A; Le Malicot K; Julié C; Blons H; Mineur L; Bennouna J; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Lepage C; Emile JF; Laurent-Puig P
JAMA Oncol; 2016 May; 2(5):643-653. PubMed ID: 26768652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
